Aliases & Classifications for Acute Mountain Sickness

MalaCards integrated aliases for Acute Mountain Sickness:

Name: Acute Mountain Sickness 49 69
High Altitude Pulmonary Edema 49 55 69
High Altitude Cerebral Edema 49 69
Altitude Sickness 49 69
Mountain Sickness 49 69
Altitude Anoxia 49

Characteristics:

Orphanet epidemiological data:

55
high altitude pulmonary edema
Prevalence: 1-9/1000000 (Europe);

Classifications:



External Ids:

Orphanet 55 ORPHA330012
UMLS via Orphanet 70 C0340100
ICD10 via Orphanet 33 J81

Summaries for Acute Mountain Sickness

MalaCards based summary : Acute Mountain Sickness, also known as high altitude pulmonary edema, is related to chronic mountain sickness and pulmonary edema, and has symptoms including hoarseness, dyspnea and coughing. An important gene associated with Acute Mountain Sickness is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Ibuprofen and Acetazolamide have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and testes, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 72 Altitude sickness, also known as acute mountain sickness (AMS), is a negative health effect of high... more...

Related Diseases for Acute Mountain Sickness

Diseases in the Acute Mountain Sickness family:

Chronic Mountain Sickness

Diseases related to Acute Mountain Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 32.3 EDN1 NOS3 VEGFA
2 pulmonary edema 30.6 ACE EDN1 NOS3 PIK3C2A
3 hypoxia 30.4 EGLN1 HIF1A HIF1AN VEGFA VHL
4 pulmonary hypertension 29.4 ACE EDN1 FLT1 HIF1A NOS3 VEGFA
5 pulmonary edema of mountaineers 11.2
6 unilateral absence of a pulmonary artery 11.1
7 cerebritis 10.6
8 acute anterolateral myocardial infarction 10.6 ACE PIK3C2A
9 hemifacial spasm 10.5 NOS3 VEGFA
10 virus associated hemophagocytic syndrome 10.5 MB PIK3C2A
11 hydrops, lactic acidosis, and sideroblastic anemia 10.5
12 malignant triton tumor 10.5 MB S100B
13 intravascular papillary endothelial hyperplasia 10.5 HIF1A VEGFA
14 interstitial myocarditis 10.5 MB PIK3C2A
15 intermediate coronary syndrome 10.4 ACE MB PIK3C2A
16 peripheral artery disease 10.4 ACE NOS3 VEGFA
17 prinzmetal's variant angina 10.4 EDN1 NOS3
18 pseudohyperkalemia, familial, 2, due to red cell leak 10.4 ACE MB PIK3C2A
19 angiokeratoma circumscriptum 10.4 FLT1 VEGFA
20 hypertensive nephropathy 10.4 ACE AGTR1 VEGFA
21 renal artery disease 10.4 ACE AGTR1 NOS3
22 glomeruloid hemangioma 10.4 FLT1 VEGFA
23 pericardial effusion 10.4 HIF1A PIK3C2A VEGFA
24 diastolic heart failure 10.4 ACE AGTR1 NOS3
25 endotheliitis 10.3
26 fiedler's myocarditis 10.3 ACE PIK3C2A
27 mitral valve disease 10.3 ACE AGTR1 NOS3
28 sexual disorder 10.3 ACE EDN1 NOS3
29 hepatopulmonary syndrome 10.3 EDN1 NOS3 VEGFA
30 exudative vitreoretinopathy 1 10.3 FLT1 HIF1A VEGFA
31 headache 10.3
32 anuria 10.2 ACE AGTR1 MB PIK3C2A
33 large cell carcinoma with rhabdoid phenotype 10.2 ENO2 VEGFA
34 malignant hypertension 10.2 ACE AGTR1 EDN1
35 intracranial cysts 10.2 ENO2 S100B
36 renal hypertension 10.2 ACE AGTR1 EDN1
37 bednar tumor 10.2 ENO2 S100B
38 fumarate hydratase deficiency 10.2 HIF1A VHL
39 autosomal dominant polycystic kidney disease 10.2 ACE EDN1 NOS3 VEGFA
40 sleep apnea 10.2 ACE EDN1 NOS3 S100B
41 acute myocardial infarction 10.2 ACE EDN1 MB PIK3C2A
42 epithelioid hemangioendothelioma 10.2 FLT1 VEGFA VHL
43 orbital cancer 10.1 ENO2 MB
44 vascular disease 10.1 ACE EDN1 NOS3 VEGFA
45 body mass index quantitative trait locus 11 10.1
46 body mass index quantitative trait locus 9 10.1
47 body mass index quantitative trait locus 8 10.1
48 body mass index quantitative trait locus 7 10.1
49 body mass index quantitative trait locus 12 10.1
50 body mass index quantitative trait locus 14 10.1

Graphical network of the top 20 diseases related to Acute Mountain Sickness:



Diseases related to Acute Mountain Sickness

Symptoms & Phenotypes for Acute Mountain Sickness

UMLS symptoms related to Acute Mountain Sickness:


hoarseness, dyspnea, coughing, cheyne-stokes respiration, apnea

MGI Mouse Phenotypes related to Acute Mountain Sickness:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 HIF1AN FLT1 MB HIF1A NOS3 EDN1
2 behavior/neurological MP:0005386 10.35 ENO2 HIF1AN FLT1 HIF1A VEGFA NOS3
3 cellular MP:0005384 10.32 HIF1A EGLN1 ENO2 HIF1AN FLT1 HSPA1B
4 homeostasis/metabolism MP:0005376 10.31 HIF1AN FLT1 MB HIF1A EGLN1 EDN1
5 growth/size/body region MP:0005378 10.3 EGLN1 ENO2 HIF1AN FLT1 MB HIF1A
6 hematopoietic system MP:0005397 10.21 HIF1A EGLN1 FLT1 MB ADRB2 VEGFA
7 endocrine/exocrine gland MP:0005379 10.13 HIF1A CCK ADRB2 VEGFA EDN1 NOS3
8 immune system MP:0005387 10.11 HIF1A EGLN1 FLT1 ADRB2 VEGFA NOS3
9 embryo MP:0005380 10.1 EGLN1 HIF1A FLT1 MB EDN1 VEGFA
10 adipose tissue MP:0005375 10.09 HIF1AN ADRB2 NOS3 AGTR1 PIK3C2A ACE
11 muscle MP:0005369 9.96 HIF1AN FLT1 MB HIF1A EGLN1 EDN1
12 nervous system MP:0003631 9.9 HIF1A EGLN1 ENO2 FLT1 ADRB2 VEGFA
13 liver/biliary system MP:0005370 9.87 EGLN1 HIF1A HIF1AN VEGFA NOS3 VHL
14 normal MP:0002873 9.61 HIF1A HIF1AN FLT1 VEGFA NOS3 EDN1
15 renal/urinary system MP:0005367 9.36 HIF1A EDN1 AGTR1 EGLN1 VHL PIK3C2A

Drugs & Therapeutics for Acute Mountain Sickness

Drugs for Acute Mountain Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1 15687-27-1 3672
2
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-66-5 1986
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Nifedipine Approved Phase 4 21829-25-4 4485
6
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
7
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
8
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
9
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
10
Metformin Approved Phase 4 657-24-9 4091 14219
11
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
13 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
18 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
19 Antioxidants Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Sildenafil Citrate Phase 4 171599-83-0
22 Dexamethasone acetate Phase 4,Phase 1,Phase 2 1177-87-3
23 calcium channel blockers Phase 4
24 diuretics Phase 4,Phase 3,Phase 1,Phase 2
25 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
26
protease inhibitors Phase 4,Phase 1,Phase 2
27 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Chelating Agents Phase 4
29 N-monoacetylcystine Phase 4,Phase 1,Phase 2
30 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Gastrointestinal Agents Phase 4,Phase 1,Phase 2
32 Tocolytic Agents Phase 4,Phase 1
33 Hematinics Phase 4
34 HIV Protease Inhibitors Phase 4,Phase 1,Phase 2
35 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1
36 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
37 Hormones Phase 4,Phase 3,Phase 1,Phase 2
38 Performance-Enhancing Substances Phase 4
39 Angiotensin II Type 1 Receptor Blockers Phase 4
40 Angiotensin Receptor Antagonists Phase 4
41 Angiotensinogen Phase 4
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
43 Anticoagulants Phase 4
44 Epoetin alfa Phase 4 113427-24-0
45 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
46 Antiemetics Phase 4,Phase 1,Phase 2
47 Phosphodiesterase 5 Inhibitors Phase 4,Phase 1,Phase 2
48 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
49 Anti-Infective Agents Phase 4,Phase 1,Phase 2
50 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 96)

# Name Status NCT ID Phase Drugs
1 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
2 A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Completed NCT01418157 Phase 4 Acetazolamide;Placebo
3 Ibuprofen vs Acetaminophen for AMS Prevention Completed NCT02244437 Phase 4 Ibuprofen;Acetaminophen
4 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Acetazolamide
5 Altitude Related Illness In Patients With Respiratory Disease Completed NCT02450968 Phase 4 Dexamethasone;Placebo
6 Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Completed NCT00627965 Phase 4 Sildenafil citrate;Placebo
7 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4 Riociguat
8 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
9 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4 acetazolamide
10 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
11 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
12 HIGH Altitude CArdiovascular REsearch in the ANDES Completed NCT01830530 Phase 4 Telmisartan;Nifedipine;placebo
13 Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude Recruiting NCT03177811 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
14 Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease Recruiting NCT03156231 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
15 Three New Ideas to Protect Special Forces From the Stress of High Altitude Active, not recruiting NCT02463357 Phase 4 Nifedipine extended release;Methazolamide;Metformin;Placebo;Nitrite
16 Induced Changes in Ventilatory Responsiveness and Altitude Exposure Terminated NCT01241513 Phase 4 NAC;Placebo
17 Altitude Sickness Prevention and Efficacy of Comparative Treatments Completed NCT02604173 Phase 3 Budesonide;Acetazolamide;Placebo
18 Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Completed NCT00664001 Phase 3
19 Drug Combination on Exercise Performance at High Altitude Completed NCT01902758 Phase 2, Phase 3 ambrisentan and theophylline;placebo
20 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Completed NCT01171794 Phase 3 Ibuprofen;Placebo
21 Inhaled Budesonide for Altitude Illness Prevention Withdrawn NCT02941510 Phase 3 Budesonide
22 NSAID RCT for Prevention of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
23 Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Unknown status NCT01682551 Phase 2 Chinese Medicine;Acetalozamide
24 Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Completed NCT03270787 Phase 1, Phase 2 Placebo;Compound danshen dripping pills
25 Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Completed NCT01536288 Phase 2 Rhodiola crenulata;placebo
26 Prevention of High Altitude Pulmonary Edema Completed NCT00274430 Phase 1, Phase 2 dexamethasone 8 mg bid;tadalafil 10mg bid
27 Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Completed NCT01187108 Phase 1, Phase 2 N-acetylcysteine;Acetazolamide;Placebo pills
28 Rapid Acclimatization to Hypoxia at Altitude Completed NCT01702025 Phase 1, Phase 2 Placebo;Aminophylline;Methazolamide;Aminophylline+Methazolamide
29 Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance Completed NCT01871142 Phase 1, Phase 2 Placebo;Aes-103;Aes-103
30 Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Not yet recruiting NCT03341676 Phase 2 Dexamethasone;Placebo
31 Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude Unknown status NCT02233582 Phase 1 Ibuprofen
32 Inhaled Budesonide and Acute Mountain Sickness Completed NCT02811016 Phase 1 Budesonide 200;Budesonide 800;Placebo
33 Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Completed NCT03154645 Phase 1 Ibuprofen;Acetazolamide
34 A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude Completed NCT01794078 Phase 1 Aminophylline 400 mg;Ambrisentan 5 mg
35 Safety Evaluation of Aminophylline and Methazolamide Completed NCT01587027 Phase 1 Aminophylline;Methazolamide;Aminophylline and Methazolamide
36 Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia Completed NCT00260819 Phase 1 Bosentan;Bosentam TRACLEER
37 Hypoxia Impairs Endothelial Function in HAPEs Completed NCT00176007 Phase 1
38 A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
39 The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension Completed NCT01566565 Phase 1 Theophylline and Bambuterol
40 The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers Completed NCT01530464 Phase 1 Aminophylline;Ambrisentan;Aminophylline plus ambrisentan
41 Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Not yet recruiting NCT03424226 Phase 1 Acetazolamide
42 Training in Hypoxia to Prevent Acute Mountain Sickness Unknown status NCT00886912
43 Chronic Mountain Sickness, Systemic Vascular Function Unknown status NCT01182792
44 Sleep and Cerebral Responses to High Altitude Unknown status NCT01565603
45 Hemodynamic Changes in Altitude Adaptation Unknown status NCT01698619
46 The Evaluation of a Mobile Device to Measure Ataxia With High Altitude Exposure Unknown status NCT02600078
47 DKA Optic Ultrasound Unknown status NCT02130180
48 Prevention of Acute Mountain Sickness by Intermittent Hypoxia Completed NCT00559832
49 The Effect of Chronic Nitrate Supplementation on Acute Mountain Sickness and Exercise Performance in Hypoxia Completed NCT03101904
50 Acclimatization Mechanisms During Ascent to 7500m Completed NCT00603122

Search NIH Clinical Center for Acute Mountain Sickness

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Acute Mountain Sickness

Anatomical Context for Acute Mountain Sickness

MalaCards organs/tissues related to Acute Mountain Sickness:

38
Lung, Endothelial, Testes, Heart, Skeletal Muscle, Brain, Pituitary

Publications for Acute Mountain Sickness

Articles related to Acute Mountain Sickness:

(show top 50) (show all 589)
# Title Authors Year
1
Pharmacological interventions for preventing acute mountain sickness: a network meta-analysis and trial sequential analysis of randomized clinical trials. ( 29166795 )
2018
2
Plasma proteomic study of acute mountain sickness susceptible and resistant individuals. ( 29352170 )
2018
3
Dietary nitrate supplementation increases acute mountain sickness severity and sense of effort during hypoxic exercise. ( 28684588 )
2017
4
Response to letter to the editor regarding "Acute mountain sickness among tourists visiting the high-altitude city of Lhasa, Tibet, China at 3658A m above sea level: a cross-sectional study". ( 28469847 )
2017
5
Acute mountain sickness amongst tourists to Lhasa. ( 28149514 )
2017
6
A Signature of Circulating microRNAs Predicts the Susceptibility of Acute Mountain Sickness. ( 28228730 )
2017
7
Inhaled budesonide does not prevent acute mountain sickness after rapid ascent to 4559a88m. ( 28890439 )
2017
8
Acute Mountain Sickness. ( 29136446 )
2017
9
Incidence and severity of acute mountain sickness and associated symptoms in children trekking on Xue Mountain, Taiwan. ( 28832689 )
2017
10
Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3450 m. ( 28798201 )
2017
11
MEDEX2015: Greater Sea-Level Fitness Is Associated with Lower Sense of Effort During Himalayan Trekking Without Worse Acute Mountain Sickness. ( 28394182 )
2017
12
Residence at Moderate Versus Low Altitude Is Effective at Maintaining Higher Oxygen Saturation During Exercise and Reducing Acute Mountain Sickness Following Fast Ascent to 4559 m. ( 28455198 )
2017
13
Heterogeneous regulation of cerebral blood flow in hypoxia; implications for dynamic cerebral autoregulation and susceptibility to acute mountain sickness. ( 28247477 )
2017
14
MEDEX 2015: Heart Rate Variability Predicts Development of Acute Mountain Sickness. ( 28418725 )
2017
15
Budesonide Versus Acetazolamide for Prevention of Acute Mountain Sickness. ( 28668540 )
2017
16
Does This Patient Have Acute Mountain Sickness?: The Rational Clinical Examination Systematic Review. ( 29136449 )
2017
17
Effects of rapid ascent on the heart rate variability of individuals with and without acute mountain sickness. ( 28251400 )
2017
18
Is acute mountain sickness related to trait anxiety? A normobaric chamber study. ( 28069461 )
2017
19
Relationship between Smoking and Acute Mountain Sickness: A Meta-Analysis of Observational Studies. ( 29259975 )
2017
20
Acute mountain sickness, arterial oxygen saturation and heart rate among Tibetan students who reascend to Lhasa after 7 years at low altitude: a prospective cohort study. ( 28698346 )
2017
21
Prophylactic Acetaminophen or Ibuprofen Result in Equivalent Acute Mountain Sickness Incidence at High Altitude: A Prospective Randomized Trial. ( 28479001 )
2017
22
IL-10 Dysregulation in Acute Mountain Sickness Revealed by Transcriptome Analysis. ( 28611780 )
2017
23
Smartphone-Enabled Heart Rate Variability and Acute Mountain Sickness. ( 28407652 )
2017
24
Wearable Physiologic Sensors and Real-Time Algorithms for Detection of Acute Mountain Sickness. ( 29074708 )
2017
25
Inhaled budesonide for acute mountain sickness. ( 28890440 )
2017
26
Findings of Cognitive Impairment at High Altitude: Relationships to Acetazolamide Use and Acute Mountain Sickness. ( 28509579 )
2017
27
Acute mountain sickness and arterial oxygen saturation. ( 26922357 )
2016
28
Prevalence of acute mountain sickness on Mount Fuji: A pilot study. ( 27147731 )
2016
29
A higher baseline somatization score at sea level as an independent predictor of acute mountain sickness. ( 27640135 )
2016
30
Acute mountain sickness in children at Jade Mountain. ( 27178162 )
2016
31
Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude trek and has fewer side effects than acetazolamide at sea level. ( 27433337 )
2016
32
Acute mountain sickness and oxygen saturation. ( 26922356 )
2016
33
Association of Cognitive Performance with Time at Altitude, Sleep Quality, and Acute Mountain Sickness Symptoms. ( 27460198 )
2016
34
Risk Determinants of Acute Mountain Sickness and Summit Success on a 6-Day Ascent of Mount Kilimanjaro (5895 m). ( 26948557 )
2016
35
Novel drugs in the management of acute mountain sickness and high altitude pulmonary edema. ( 26766920 )
2016
36
Subjective assessment of acute mountain sickness: investigating the relationship between the Lake Louise Self-Report, a visual analogue scale and psychological well-being scales. ( 27722064 )
2016
37
Vascular Endothelial Function Assessed by Postischemic Diastolic Blood Pressure Is Associated with Acclimatization and Acute Mountain Sickness. ( 26977539 )
2016
38
Incidence and risk factors associated with acute mountain sickness in children trekking on Jade Mountain, Taiwan. ( 26782126 )
2016
39
Evidence for cerebral edema, cerebral perfusion, and intracranial pressure elevations in acute mountain sickness. ( 27099800 )
2016
40
Endothelin-1 Plasma Levels and Acute Mountain Sickness. ( 27058016 )
2016
41
High Altitude and Acute Mountain Sickness and Changes in Circulating Endothelin-1, Interleukin-6, and Interleukin-17a. ( 26680502 )
2016
42
Inevitable Acclimatization and Acute Mountain Sickness. ( 26972140 )
2016
43
Acute Mountain Sickness and Vascular Endothelial Dysfunction. ( 27295418 )
2016
44
Acute mountain sickness and duration of pre-exposure to high altitude. ( 27483198 )
2016
45
Differences Between the "Chinese AMS Score" and the Lake Louise Score in the Diagnosis of Acute Mountain Sickness. ( 27227918 )
2016
46
Association between smoking and the risk of acute mountain sickness: a meta-analysis of observational studies. ( 27980800 )
2016
47
Analysis of High-altitude Syndrome and the Underlying Gene Polymorphisms Associated with Acute Mountain Sickness after a Rapid Ascent to High-altitude. ( 27982053 )
2016
48
Letter to the Editor re: Use of Statins for Prophylaxis Against Acute Mountain Sickness: Response. ( 26802382 )
2016
49
In Response to Risk Determinants of Acute Mountain Sickness by Lawrence and Reid. ( 27939594 )
2016
50
Acute mountain sickness among tourists visiting the high-altitude city of Lhasa at 3658A m above sea level: a cross-sectional study. ( 27252854 )
2016

Variations for Acute Mountain Sickness

Expression for Acute Mountain Sickness

Search GEO for disease gene expression data for Acute Mountain Sickness.

Pathways for Acute Mountain Sickness

Pathways related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B VEGFA
2 12.74 AGTR1 BDKRB2 EGLN1 HIF1A VEGFA VHL
3
Show member pathways
12.48 EDN1 HSPA1A HSPA1B NOS3 VEGFA
4
Show member pathways
12.27 CCK FLT1 NOS3 VEGFA
5
Show member pathways
12.15 ADRB2 AGTR1 BDKRB2 NOS3
6
Show member pathways
12.12 FLT1 NOS3 PIK3C2A VEGFA
7 11.81 AGTR1 EDN1 NOS3 VEGFA
8
Show member pathways
11.77 FLT1 HIF1A NOS3 VEGFA VHL
9
Show member pathways
11.71 FLT1 NOS3 PIK3C2A
10 11.71 EGLN1 FLT1 HIF1A HIF1AN NOS3
11
Show member pathways
11.7 ACE AGTR1 BDKRB2 NOS3
12 11.59 ACE ADRB2 AGTR1
13 11.57 EDN1 EGLN1 HIF1A VEGFA
14 11.56 EDN1 EGLN1 ENO2 FLT1 HIF1A NOS3
15
Show member pathways
11.53 HSPA1A HSPA1B NOS3
16 11.22 EDN1 EGLN1 HIF1A HIF1AN VEGFA
17
Show member pathways
11.18 EDN1 HIF1A VEGFA
18 11.09 EGLN1 FLT1 HIF1AN VEGFA VHL
19 11.01 EDN1 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B
20 11 FLT1 HIF1A NOS3 VEGFA
21 10.83 HIF1A HIF1AN VHL
22 10.56 HIF1A HIF1AN VEGFA
23 10.5 MB NOS3

GO Terms for Acute Mountain Sickness

Cellular components related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 ACE EDN1 EGLN1 ENO2 FLT1 HIF1A

Biological processes related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.93 FLT1 HIF1A NOS3 VEGFA
2 positive regulation of angiogenesis GO:0045766 9.81 FLT1 HIF1A NOS3 VEGFA
3 regulation of blood pressure GO:0008217 9.79 ACE EDN1 NOS3
4 positive regulation of MAP kinase activity GO:0043406 9.78 EDN1 FLT1 VEGFA
5 cellular response to hypoxia GO:0071456 9.73 EDN1 HIF1A S100B VEGFA
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.67 HIF1A NOS3 VEGFA
7 protein refolding GO:0042026 9.65 HSPA1A HSPA1B
8 response to hypoxia GO:0001666 9.65 EDN1 EGLN1 HIF1A MB VEGFA
9 regulation of cell death GO:0010941 9.63 HSPA1A HSPA1B
10 positive regulation of erythrocyte differentiation GO:0045648 9.63 HIF1A HSPA1A HSPA1B
11 negative regulation of inclusion body assembly GO:0090084 9.62 HSPA1A HSPA1B
12 positive regulation of tumor necrosis factor-mediated signaling pathway GO:1903265 9.61 HSPA1A HSPA1B
13 positive regulation of receptor biosynthetic process GO:0010870 9.6 EDN1 HIF1A
14 oxygen homeostasis GO:0032364 9.59 EGLN1 HIF1A
15 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.58 EDN1 NOS3
16 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.58 ACE AGTR1
17 blood vessel morphogenesis GO:0048514 9.58 EDN1 FLT1 HIF1A
18 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.57 ACE VEGFA
19 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 HIF1A VEGFA
20 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.55 HIF1AN VHL
21 positive regulation of microtubule nucleation GO:0090063 9.54 HSPA1A HSPA1B
22 cellular heat acclimation GO:0070370 9.52 HSPA1A HSPA1B
23 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.5 FLT1 HIF1A VEGFA
24 positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070434 9.48 HSPA1A HSPA1B
25 positive regulation of chemokine-mediated signaling pathway GO:0070101 9.37 EDN1 HIF1A
26 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.35 EGLN1 HIF1A HIF1AN VEGFA VHL
27 regulation of blood vessel diameter GO:0097746 9.33 ACE ADRB2 AGTR1
28 regulation of vasoconstriction GO:0019229 8.92 ACE AGTR1 BDKRB2 EDN1
29 negative regulation of apoptotic process GO:0043066 10.04 HIF1A HSPA1A HSPA1B VEGFA VHL
30 positive regulation of cell proliferation GO:0008284 10.04 CCK EDN1 FLT1 S100B VEGFA

Molecular functions related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled GO:0042623 9.26 HSPA1A HSPA1B
2 C3HC4-type RING finger domain binding GO:0055131 9.16 HSPA1A HSPA1B
3 enzyme binding GO:0019899 9.1 ADRB2 EGLN1 HIF1A HSPA1A HSPA1B VHL
4 bradykinin receptor binding GO:0031711 8.96 ACE AGTR1

Sources for Acute Mountain Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....